Fexofenadine
Allegr, Allegra (fexofenadine) is a small molecule pharmaceutical. Fexofenadine was first approved as Allegra on 1996-07-25. It is used to treat allergic rhinitis perennial and urticaria in the USA. The pharmaceutical is active against histamine H1 receptor.
Download report
Favorite
Top OTC Drugs
Commercial
Trade Name
FDA
EMA
Allegra (generic drugs available since 2005-09-01)
CombinationsAllegr (generic drugs available since 2005-09-01)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Fexofenadine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ALLEGRA ALLERGY | Sanofi | N-020872 OTC | 2011-01-24 | 1 products, RLD |
| ALLEGRA HIVES | Sanofi | N-020872 OTC | 2011-01-24 | 1 products, RLD, RS |
| ALLEGRA ALLERGY | Sanofi | N-020872 OTC | 2011-01-24 | 1 products, RLD, RS |
| CHILDREN'S ALLEGRA ALLERGY | Sanofi | N-201373 OTC | 2011-01-24 | 1 products, RLD, RS |
Show 8 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| allegra hives 24hr | New Drug Application | 2023-04-10 |
| allergy relief | ANDA | 2023-05-04 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| allergic rhinitis perennial | EFO_1001417 | D012221 | J30.89 |
| urticaria | EFO_0005531 | D014581 | L50 |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Fexofenadine Hydrochloride, Children'S Allegra Allergy, Chattem Sanofi | |||
| 8933097 | 2030-08-02 | DP | |
HCPCS
No data
Clinical
Clinical Trials
74 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Allergic rhinitis seasonal | D006255 | EFO_0003956 | J30 | — | 1 | 1 | 9 | — | 11 |
| Allergic rhinitis | D065631 | J30.9 | — | 2 | — | 8 | — | 10 | |
| Pruritus | D011537 | HP_0000989 | L29 | 1 | 1 | 1 | 2 | — | 5 |
| Rhinitis | D012220 | EFO_0008521 | J31 | — | 1 | 3 | 1 | — | 4 |
| Gout | D006073 | EFO_0004274 | M10 | — | — | — | 2 | — | 2 |
| Urticaria | D014581 | EFO_0005531 | L50 | 1 | — | — | 1 | — | 2 |
| Chronic urticaria | D000080223 | L50.8 | 1 | — | — | 1 | — | 2 | |
| Allergic rhinitis perennial | D012221 | EFO_1001417 | J30.89 | — | — | 1 | 1 | — | 2 |
| Renal dialysis | D006435 | EFO_0010690 | Z99.2 | — | — | — | 1 | — | 1 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asthma | D001249 | EFO_0000270 | J45 | — | — | 3 | — | — | 3 |
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | 1 | 1 | 1 | — | — | 2 |
| Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | — | 1 | — | — | 1 | |
| Chronic progressive multiple sclerosis | D020528 | — | — | 1 | — | — | 1 | ||
| Diabetic nephropathies | D003928 | EFO_0000401 | — | — | 1 | — | — | 1 | |
| Cold temperature | D003080 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Gastroesophageal reflux | D005764 | EFO_0003948 | K21 | — | 1 | — | — | — | 1 |
| Nephrolithiasis | D053040 | N20.0 | — | 1 | — | — | — | 1 | |
| Edema | D004487 | R60.9 | — | 1 | — | — | — | 1 | |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 13 | — | — | — | 1 | 14 | ||
| Drug interactions | D004347 | 2 | — | — | — | — | 2 | ||
| Magnetic resonance imaging | D008279 | 1 | — | — | — | — | 1 | ||
| Oral administration | D000284 | 1 | — | — | — | — | 1 | ||
| Pharmacokinetics | D010599 | 1 | — | — | — | — | 1 | ||
| Heart failure | D006333 | EFO_0003144 | I50 | 1 | — | — | — | — | 1 |
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | — | — | — | — | 1 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 1 | — | — | — | — | 1 |
| Pulmonary arterial hypertension | D000081029 | 1 | — | — | — | — | 1 | ||
| Non-small-cell lung carcinoma | D002289 | 1 | — | — | — | — | 1 |
Show 3 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Exercise | D015444 | EFO_0000483 | — | — | — | — | 1 | 1 | |
| Food-drug interactions | D018565 | — | — | — | — | 1 | 1 | ||
| Renal colic | D056844 | EFO_1001412 | N23 | — | — | — | — | 1 | 1 |
| Transcatheter aortic valve replacement | D065467 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | FEXOFENADINE |
| INN | fexofenadine |
| Description | Fexofenadine is a piperidine-based anti-histamine compound. It has a role as a H1-receptor antagonist and an anti-allergic agent. It is a member of piperidines and a tertiary amine. It is functionally related to an isobutyric acid. |
| Classification | Small molecule |
| Drug class | Antihistamine; H1 receptor antagonist |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 83799-24-0 |
| RxCUI | 87636 |
| ChEMBL ID | CHEMBL914 |
| ChEBI ID | 5050 |
| PubChem CID | 3348 |
| DrugBank | DB00950 |
| UNII ID | E6582LOH6V (ChemIDplus, GSRS) |
Target
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,821 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
23,569 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more